A novel multipotent sigma 1/M1 muscarinic activator for a comprehensive therapeutic strategy in Alzheimer’s disease
Anavex Encouraged By Scientific Data Confirming Sigma-1 Receptor Agonist Extends Survival in ALS (Lou Gehrig’s Disease)
Sigma-1 Receptor Implicated in Cell Survival of Rare Neurodegenerative Diseases – Expanding the Opportunity for Application of ANAVEX PLUS in Rare Diseases
